T lymphocytes engineered to express a chimeric antigen receptor (CAR) are being celebrated as a major breakthrough of anticancer immunotherapy. Natural killer cells have not received similar attention as CAR effectors, although the use of these relatively short-lived cytotoxic cells is associated with several advantages.
The latter American Society of Hematology (ASH) meeting, which took place last December in New Orleans, was dominated by the enthusiasm on the anti-leukemia effects of T lymphocytes engineered to express a CD19-targeting chimeric antigen receptor (CAR). 1 Fourteen out of 16 pediatric patients with relapsed or advanced acute lymphoblastic leukemia (ALL) entered a remission in response to the adoptive transfer of these cells. A similar outcome was documented for adults with chronic lymphocytic leukemia.
CAR-expressing T cells are usually generated from autologous T cells, but T lymphocytes from allogeneic donors are also being explored in this sense, especially upon relapse after stem cell transplantation.
2 CAR-bearing T cells are usually activated with anti-CD3/ CD28 beads and expanded in culture flasks (such as the Wave R system) in the presence of interleukin (IL)-2. CARs against an expanding array of cell surfaceexposed tumor-associated antigens (TAAs) have been and continue to be engineered. 3 Since the majority of these TAAs are not tumor specific, CARexpressing T cells can cross-react with healthy cells, mediating an "on-target/ off-tumor" side effect. For example, T cells expressing a CD19-targeting CAR can cause a profound and long-lasting B-cell deficiency as they eliminate normal B cells. 4 T lymphocytes bearing a CAR specific for interleukin 3 receptor, α (ILR3A, also known as CD123) kill not only leukemic cells but also bone marrow cells that express the same receptor, leading to prolonged and profound marrow suppression. 5 In some cases this on-target/off-tumor side effect can be fatal, as it happened in a patient with metastatic colon carcinoma who received T cells engineered to express a HER2 targeting CAR. In this case, the side effects of CAR-expressing T cells on low level HER2 expressing lung epithelium led to fatal pulmonary complications combined with a massive cytokine release.
It has been suggested that the antineoplastic activity of CAR-expressing T cells is related to and dependent on their persistence in the patient circulation and malignant tissue. If this were indeed the case, the on-target/off-tumor effects would also persist. For CD19-redirecetd T cells, this would entail a prolonged depletion of normal B cells and hence long-term defects in humoral immunity.
As recent clinical trials have suggested, antigen loss cancer variants can emerge as a result of the selective pressure imposed by immunotherapeutic interventions, often driving disease relapse. 1 In this setting, TAA-specific T cells would continue to mediate on-target/off tumor effects, such as the suppression of normal B cells or bone marrow precursors. A potential solution to this issue is provided by the transduction of T cells with CARcoding mRNAs, usually resulting in the loss of expression over a few days. 7 Indeed, most CAR-expressing T cells currently tested in clinical trials are obtained with lentiviral constructs, which integrate into
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Natural killer (NK) cells may represent alternative cytotoxic effectors for CARdriven cytolysis. Allogeneic NK cells are expected to induce an immune response and be rejected after a few days, and even autologous NK cells should disappear relatively rapidly from the circulation, owing to their limited lifespan. NK cells have additional advantages over T cells ( Table 1) . In particular, while T lymphocytes only kill their targets by a CAR-specific mechanism, NK cells are endowed with spontaneous cytotoxic activity and can trigger the demise of target cells in a TAA-unrestricted manner via specific natural cytotoxicity receptors (NCRs), including NCR3 (also known as NKp30), NCR2 (also known as NKp44), NCR1 (also known as NKp46), and killer cell lectin-like receptor subfamily K, member 1 (KLRK1, best known as NKG2D). NK cells also express the Fc fragment of IgG, low affinity III, receptor (FcγRIII), that binds the Fc fragment of antibodies to elicit antibody-dependent cell-mediated cytotoxicity (ADCC). This specific feature of NK cells would enable the combination of 2 targeted therapies recognizing different (or the same) TAA(s), namely CAR-expressing NK cells and a TAA-specific monoclonal antibody.
Additional features of NK cells could make them better and potentially safer CAR drivers than T cells. For instance, NK cells produce a host of cytokines that are different from those produced by T cells, including interferon γ (IFNγ) and granulocyte macrophage colonystimulating factor (GM-CSF). The cytokine storm initiated by the infusion of CAR-expressing T cells is indeed largely mediated by their pro-inflammatory cytokines such as tumor necrosis factor α (TNFα), IL-1, and IL-6. It is also known that NK cells are "serial killers." Thus, time-lapse videomicroscopy studies have shown that NK as well as NK-92 cells (a continuously-growing, highly-active, NK cell-derived cell line) diligently move from one target to the next one, killing on as many as 7-10 cells. 8 Evidence for such a serial killing by T cells is lacking at this point.
Nonetheless, there are some obstacles for the use of circulating NK cells for CAR-based immunotherapy. Like T lymphocytes, NK cells are obtained (from patients or donors) by leukopheresis, which can be time-consuming, costly and occasionally requiring central venous access. Since only about 10% of circulating Abbreviations: CAR, chimeric antigen receptor; fcR, fc receptor; GvH, graft-vs.-host; iL, interleukin; nK, natural killer; tnfSf9, tumor necrosis factor superfamily, member 9. 
